This study aims to describe the prevalence of additional autoimmune diseases and their specific antibodies at type 1 diabetes (T1D) diagnosis, and their incidence rate during follow-up, for children and adolescents. It also aims to describe the characteristics of the pediatric cohort followed since 2014 for type 1 diabetes by one of France's centers of reference for paediatric diabetes.
Study Type
OBSERVATIONAL
Enrollment
250
There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
Hôpital d'Enfants de Brabois
Vandœuvre-lès-Nancy, Lorraine, France
Number of additional autoimmune diseases at type 1 diabetes diagnosis
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations
Time frame: up to 3 weeks after type 1 diabetes diagnosis
Type of additional autoimmune diseases at type 1 diabetes diagnosis
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations
Time frame: up to 3 weeks after type 1 diabetes diagnosis
Characteristics of patients, if additional autoimmune disease is present or absent
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic
Time frame: up to 3 weeks after type 1 diabetes diagnosis
Occurence or non-occurence of at least one additional autoimmune diseases during follow-up
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations
Time frame: From type 1 diabetes diagnostic to last news date, an average of 3 years
Occurence or non-occurence of each type of additional autoimmune disease during follow-up
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations, in this outcome studied each one separately
Time frame: From type 1 diabetes diagnostic to last news date, an average of 3 years
Presence of antibodies specific to an additional autoimmune disease at type 1 diabetes diagnostic
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies)
Time frame: up to 3 weeks after type 1 diabetes diagnosis
Characteristics of patients, if at least one type of antibodies specific to an autoimmune disease is present or absent at type 1 diabetes diagnostic
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic
Time frame: up to 3 weeks after type 1 diabetes diagnosis
Characteristics of patients, for each type of antibodies specific to an autoimmune disease, present or absent at type 1 diabetes diagnostic
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic
Time frame: up to 3 weeks after type 1 diabetes diagnosis
Occurence or non-occurence of at least one type of antibody specific to an additional autoimmune disease
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies)
Time frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
Occurence or non-occurence of antibodies specific to each additional autoimmune disease listed in outcome 5
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies)
Time frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
Description of the characteristics of all the patients followed in our cohort of pediatric type 1 diabetes
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic, presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases
Time frame: Up to 3 weeks after type 1 diabetes diagnosis
Description of the autoimmune characteristics of all the patients followed in our cohort of pediatric type 1 diabetes
presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases
Time frame: during follow-up : From type 1 diabetes diagnosis to last news date, from 1 to 6 years
If detection of antibodies specific to an additional autoimmune disease : delay between detection of these antibodies and diagnosis of the corresponding autoimmune disease
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies)
Time frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
If patient diagnosed with Hashimoto when type 1 diabetes is diagnosed, proportion of patients with thyroid dysfunction
Thyroid dysfunction : hormonal dysfunction associated to Hashimoto
Time frame: Up to 3 weeks after type 1 diabetes diagnosis
Occurence of thyroid dysfunction in patients with type 1 diabetes and Hashimoto
Occurence during type 1 diabetes follow-up of thyroid dysfunction in patients with Hashimoto
Time frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
Proportion of patients with thyroid dysfunction due to Hashimoto needing a specific treatment
Time frame: Up to 3 weeks after type 1 diabetes diagnosis
Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto
Time frame: From type 1 diabetes diagnosis to last news date, from 1 to 6 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.